Traffic:
10E
10W
15N
15S
57N
57S
60E
60W
210E
210W
This Site
Web Search
powered by
YAHOO! SEARCH
Subscriber Services
|
Home Delivery
|
e-Edition
|
Alerts
|
RSS
Home
News
Ontario
Rancho Cucamonga
Pomona
Upland
Claremont
Montclair
Chino Valley
California
Crime & Public Safety
Elections
Education
S.B. County Watch
Upland Watch
I.E.: Medicare Testing Ground
Sports
Buy Event Tickets Now
Golf - Tee Times and Courses
Preps
Reign Hockey
Rancho Cucamonga Quakes
Local Colleges
USC
UCLA
Lakers
Clippers
Dodgers
Angels
Ducks
Soccer
Motor Sports
Horse Racing
Live Odds
Business
Autos
Real Estate News
Technology
Opinions
Editorial
Letters
Columnists
Blogs
LA.COM
Buy Tickets
Movies
TV
Music
Shopping & Beauty
Recreation
Neighborhood
Arts
Living
Dining
Find A Restaurant
Lottery
Horoscopes
Travel
Trevor's Travels
Health
Crossword Puzzle
Local Casinos
Foothills Magazine
Info
Subscribe For Home Delivery
Contact Us
RSS
Podcast
Subscriber Services
Place An Ad
NIE
Classified
Place an Ad
Homes
Jobs
Auto
Search autos
Buy/Sell a car
Research/Financing a car
Find a dealer
Shopping
This week's ads
Obits
Directories
Local Business
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Sagimet Biosciences Inc.
Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit
September 12, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Tickers
SGMT
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
September 04, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Tickers
SGMT
Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
August 14, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Tickers
SGMT
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
August 01, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Tickers
BRNS
RCUS
SGMT
SNDX
Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat
June 10, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Tickers
SGMT
Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024
June 06, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Tickers
SGMT
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024
May 16, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Tickers
SGMT
Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
May 15, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Tickers
SGMT
Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
May 07, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Tickers
SGMT
Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer
May 06, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Tickers
SGMT
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
April 22, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Tickers
SGMT
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
March 27, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Tickers
SGMT
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
March 25, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Tickers
IPSC
MIRM
RPHM
SGMT
Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
March 25, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Tickers
SGMT
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
February 29, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Tickers
SGMT
Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock
January 25, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Tickers
SGMT
Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock
January 23, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Tickers
SGMT
Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH
January 22, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Tickers
SGMT
Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic
December 04, 2023
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Tickers
SGMT
Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit
November 28, 2023
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Tickers
SGMT
Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference
November 22, 2023
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Tickers
SGMT
Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
November 13, 2023
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Tickers
SGMT
Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting® 2023
October 24, 2023
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Tickers
SGMT
Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference
October 18, 2023
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Tickers
SGMT
Sagimet Biosciences Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent Glioblastoma
September 27, 2023
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Tickers
SGMT
Sagimet Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
August 21, 2023
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Tickers
SGMT
Sagimet Biosciences Announces Closing of Underwriters’ Option to Purchase Additional Shares of Series A Common Stock in Connection with its Upsized Initial Public Offering
August 15, 2023
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Tickers
SGMT
Sagimet Biosciences Announces Leadership Changes
July 20, 2023
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Tickers
SGMT
Sagimet Biosciences Announces Pricing of Upsized Initial Public Offering
July 13, 2023
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Presents Positive Phase 2b FASCINATE-2 Clinical Trial Interim Data for Denifanstat for the Treatment of NASH at EASL Congress 2023
June 23, 2023
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Privacy Policy
|
Terms of Use
|
MNG Corporate Site Map
|
Copyright